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Abstract
Background:	 Finding	 the	 optimal	 duration	 of	 anticoagulant	 treatment	 following	 an	
acute	event	of	deep	vein	thrombosis	(DVT)	is	challenging.	Residual	venous	obstruction	
(RVO)	has	been	 identified	as	a	 risk	 factor	 for	 recurrence,	but	data	on	management	
strategies	incorporating	the	presence	of	RVO	and	associated	recurrence	rates	in	de-
fined	clinical	care	pathways	(CCP)	are	lacking.
Objectives:	We	aimed	to	investigate	the	long-	term	clinical	outcomes	and	predictors	of	
venous	thromboembolism	(VTE)	recurrence	in	a	contemporary	cohort	of	patients	with	
proximal	DVT	and	managed	in	a	CCP	incorporating	the	presence	of	RVO.
Patients:	All	patients	treated	at	the	Maastricht	University	Medical	Center	within	an	
established	clinical	care	pathway	from	June	2003	through	June	2013	were	prospec-
tively	followed	for	up	to	11	years	in	a	prospective	management	study.
Results:	Of	479	patients	diagnosed	with	proximal	DVT,	474	completed	the	two-	year	
CCP	(99%),	and	457	 (94.7%)	the	extended	follow-	up	 (2231.2	patient-	years;	median	
follow-	up	4.6	years).	Overall	VTE	recurrence	was	2.9	per	100	patient-	years,	1.3	if	pro-
voked	by	surgery,	2.1	if	a	non-	surgical	transient	risk	factor	was	present	and	4.0	if	un-
provoked.	Predictors	of	recurrent	events	were	unprovoked	VTE	(adjusted	hazard	ratio	
[HR]	4.6;	95%	CI	1.7,	11.9),	elevated	D-	dimer	one	month	after	treatment	was	stopped	
(HR	3.3;	1.8,	6.1),	male	sex	(HR	2.8;	1.5,	5.1),	high	factor	VIII	(HR	2.2;	1.2,	4.0)	and	use	
of	contraceptives	(HR	0.1;	0.0,	0.9).
Conclusions:	Patients	with	DVT	managed	within	an	established	clinical	care	pathway	
incorporating	the	presence	of	RVO	had	relatively	low	incidences	of	VTE	recurrence.
K E Y W O R D S
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1  | INTRODUCTION
The	optimal	management	 strategy	 for	 the	prevention	of	 recurrent	
	venous	thromboembolism	(VTE)	is	still	uncertain.	Venous	thrombo-
embolism	contributes	significantly	to	global	disease	burden.1	Within	
the	 European	 Union,	 it	 is	 estimated	 that	 the	 annual	 incidence	 of	
deep-	vein	thrombosis	(DVT)	and	pulmonary	embolism	(PE)	cases	is	
684	000	and	435	000,	respectively,	and	VTE-	related	deaths	exceed	
543	000.2	While	prevention	of	recurrent	VTE	is	important	to	reduce	
the	 burden	 of	 disease,1	 anticoagulation	 treatment,	 the	 mainstay	
of	VTE	 prevention,	 is	 accompanied	 by	 a	 significant	 risk	 of	 bleed-
ing	 complications.3	 Efficient	 prevention	 thus	 critically	 depends	on	
optimal	 assessment	 of	 recurrence	 risk	 in	 individual	 patients.	 Even	
though	a	number	of	clinical	criteria,	laboratory	assays,	and	even	im-
aging	tests	have	been	proposed	as	risk	factors	for	recurrent	VTE,4,5 
their clinical value is limited.4	Recent	guidelines	 comment	on	pre-
vious	study	results	and	suggest	that	the	demonstration	of	residual	
vein	obstruction	(RVO)	at	the	end	of	the	regular	period	of	anticoag-
ulation	treatment	might	improve	risk	assessment	and	management	
of	recurrent	VTE.3,6	Indeed,	observational	data	has	established	RVO	
as	a	risk	factor	for	recurrent	VTE	with	a	relative	risk	of	about	1.5.7–
11	These	data	were	confirmed	in	a	randomized	controlled	trial	that	
compared	RVO-	guided	anticoagulation	therapy	vs	stopping	antico-
agulation	treatment	after	3	to	6	months.10	However,	it	is	not	known	
if	RVO	is	useful	for	risk	assessment	 in	clinical	practice,	although	it	
is	used	 in	 combination	with	other	diagnostic	 and	prognostic	 tools	
in	 a	management	 strategy.	 In	 particular,	 the	 effects	 of	 a	manage-
ment	 strategy	comprising	 the	presence	of	RVO	 in	clinical	practice	
are	unknown.
Applying	evidence-	based	health	care	is	a	difficult	task,	particularly	
in	VTE	patients.	Clinical	care	pathways	(CCPs)	have	been	introduced	to	
guide	diagnostic	and	 therapeutic	decisions	 for	patients	with	defined	
clinical	 problems	 in	 complex	 organisations.12	 CCPs	 aim	 to	 translate	
evidence-	based	medicine	 into	clinical	practice,	 improve	collaboration	
among	 multiple	 specialized	 care	 providers	 and	 standardize	 health	
care	procedures.13,14	CCPs	have	been	 introduced	for	patients	with	a	
variety	of	 clinical	 problems	 including	venous	 thromboembolism.15–19 
However,	knowledge	on	the	long-	term	effects	of	CCPs	on	clinical	out-
comes	of	patients	with	VTE	is	lacking.	The	present	investigation	aimed	
to	 investigate	 both	 the	 long-	term	 clinical	 outcomes	 in	 patients	with	
DVT	managed	in	a	defined	CCP	incorporating	the	presence	of	RVO	and	
also	to	determine	risk	 factors	 for	VTE	recurrence	 in	a	contemporary	
cohort	of	patients	with	proximal	DVT	managed	within	a	defined	CCP.
2  | METHODS
2.1 | Study design and population
The	 present	 study	 represents	 a	 observational	 health	 care	 manage-
ment	study	and	no	control	group	was	assessed.	Clinical	outcomes	of	
all	patients	that	were	treated	within	a	clinical	care	pathway	(CCP)	of	
the	 Maastricht	 University	 Medical	 Center	 (MUMC)	 between	 2003	
and	 2013	were	 investigated.	MUMC	 is	 the	 only	 tertiary	 hospital	 in	
the	Dutch	 province	 of	 Limburg,	 the	Netherlands.	 Consecutive	 adult	
patients	diagnosed	with	an	acute,	objectively	confirmed	first	proximal	
DVT	(popliteal	vein,	femoral	vein,	common	femoral	vein,	or	iliac	vein)	
between	2003	and	2013	were	followed	for	two	years	within	the	CCP,	
and	additional	outcomes	data	was	collected	 for	an	extended	period.	
No	 exclusion	 criteria	were	 applied.	However,	 certain	 patient	 groups	
were	usually	not	treated	within	the	CCP:	distal	DVT,	DVT	complicated	
by	PE,	patients	who	follow	further	treatment	in	other	institutions	than	
MUMC,	and	patients	with	cancer.	The	study	was	carried	out	in	accord-
ance	with	the	Declaration	of	Helsinki,	and	the	study	protocol	and	col-
lection	of	data	was	approved	by	the	 local	MUMC	ethical	committee	
(METC	15-	4-	256).
2.2 | Clinical care pathway
In	2003,	a	CCP	was	implemented	at	the	MUMC	to	guide	management	
of	patients	diagnosed	with	proximal	DVT.	All	patients	objectively	di-
agnosed	 with	 proximal	 DVT	 (popliteal	 vein,	 femoral	 vein,	 common	
femoral	vein,	or	iliac	vein)	at	the	MUMC	are	managed	in	a	specialized	
outpatient	clinic	according	to	a	strict	protocol.	Regular	visits	are	sched-
uled	0.5,	3,	6,	12,	and	24	months	after	diagnosis.	Structured	history	and	
physical	 examination	as	well	 as	 an	assessment	of	 clinical	 risk	 factors	
are	performed	at	the	first	visit.	The	Villalta	score	is	performed	at	every	
visit.20	Laboratory	tests	are	performed	1	month	after	cessation	of	an-
ticoagulation	treatment,	and	12	and	24	months	after	diagnosis	(levels	
of	D-	dimer,	 factor	VIII,	 and	C-reactive	protein	 [CRP]).	Thrombophilia	
markers	are	not	ordered	routinely.	RVO	is	assessed	by	ultrasonography	
1	week	before	the	intended	cessation	of	anticoagulant	treatment	(after	
3	or	6	months,	respectively).
2.3 | Risk assessment and treatment decisions
The	criteria	by	which	the	risk	of	recurrent	VTE	is	assessed	are	de-
lineated	by	a	strict	protocol	and	instructions	are	in	line	with	current	
Essentials
•	 Outcomes	of	clinical	care	pathways	(CCP)	for	treatment	of	deep	vein	thrombosis	(DVT)	are	unknown.
•	 We	followed	479	DVT	patients	treated	within	a	CCP	incorporating	RVO	for	a	median	of	five	years.
•	 Patients	had	relatively	low	incidences	of	VTE	recurrences	and	deaths.
•	 Unprovoked	DVT,	D-dimer,	male	sex,	factor	VIII	and	contraceptive	use	predicted	recurrent	events.
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guidelines.	The	major	principles	are	 illustrated	 in	Figure	1.	Patients	
are	 assigned	 to	 three	 different	 categories:	 (i)	 patients	with	 a	 pro-
voked	DVT	 in	 the	course	of	a	 reversible	 risk	 factor	such	as	 recent	
surgery	are	assigned	to	three	months	of	anticoagulation	treatment;	
(ii)	 patients	with	 an	unprovoked	DVT	are	 assigned	 to	6	months	of	
anticoagulation	 therapy	 and	 extensive	 risk	 assessment;	 (iii)	 high-	
risk	 patients	 are	 assigned	 to	 an	 indefinite	 anticoagulant	 treatment	
regimen.	 “Provoked	DVT”	was	 defined	 as	DVT	with	 the	 presence	
of	 a	 reversible	 risk	 factor	 (surgery	within	 2	months,	 contraceptive	
use,	pregnancy,	long-	distance	travel	of	more	than	10	hours,	and	im-
mobilization).	 “Unprovoked	DVT”	was	defined	as	DVT	without	 the	
presence	of	a	reversible	risk	factor	(see	above).	“High-	risk	patients”	
were	defined	as	unprovoked	DVT	in	the	presence	of	recurrent	VTE,	
elevated	D-	dimer,	 high	 factor	 VIII,	 known	 high-	risk	 thrombophilia,	
inflammation,	or	active	cancer.	High	risk	thrombophilia	were	defined	
as	protein	S	or	C	deficiency,	homozygous	factor	V-	Leiden	mutation,	
antithrombin	 deficiency,	 or	 antiphospholipid	 antibody	 syndrome.21 
Antithrombin	 deficiency	 was	 defined	 as	 functional	 antithrombin	
<70%.22	 Protein	 S	 deficiency	was	defined	 as	 free	protein	 S	 below	
reference	range	(<2.5th	percentile),	and	protein	C	deficiency	was	de-
fined	as	protein	C	below	reference	range	(<	2.5th	percentile)—both	
in	the	absence	of	vitamin	K-	deficiency.23	Inflammation	was	defined	
as	the	presence	of	an	systemic	inflammatory	disease	such	as	Crohn’s	
disease,	ulcerative	colitis,	or	connective	tissue	disease.	The	presence	
of	 elevated	D-	dimer,	 high	 factor	VIII,	 and	persistent	 elevated	CRP	
was	considered	for	risk	assessment	1	month	after	stop	anticoagula-
tion only.
Presence	of	RVO	at	 the	 time	of	planned	 treatment	discontin-
uation	is	the	primary	risk	factor	upon	which	treatment	duration	is	
further	tailored.	If	no	RVO	is	present	at	this	time	point,	anticoag-
ulation	 treatment	will	 be	 stopped.	 In	 the	 case	 of	 detected	 RVO,	
anticoagulation	will	be	prolonged	for	another	3	months	(provoked	
DVT),	or	6	months	(unprovoked),	respectively.	Treatment	will	only	
be	prolonged	once.	Deviations	 from	 the	protocol	 could	be	made	
at	 the	 discretion	 of	 the	 treating	 physician	 to	 address	 patients	
preferences.
2.4 | Assessment of RVO
RVO	 was	 assessed	 using	 compression	 ultrasound	 (CU)	 as	 previ-
ously described24	 and	 a	 protocol	 has	 been	 implemented	 for	 con-
ducting	 a	 series	 of	 standardized	 ultrasound	 measurements	 as	
follows.	Measurements	were	taken	at:	(i)	the	common	femoral	vein,	
just	 below	 the	 inguinal	 ligament,	 and	 (ii)	 at	 the	popliteal	 vein.	No	
iliacal	 or	 calf	 veins	were	 assessed.	 B-	mode	 images	were	 taken	 in	
a	 transverse	 plane.	 RVO	was	 defined	 according	 to	 the	 definition	
of	Prandoni	as	residual	vein	diameter	during	compression	of	more	
than 2 mm.24	Several	studies	confirmed	an	acceptable	accuracy	and	
inter-	observer	 reproducibility	 of	 this	 method24–27 and agreement 
between	observers	was	achieved	by	close	 teamwork	among	team	
members.	 A	 formal	 assessment	 of	 the	 inter-	observer	 agreement	
was not conducted.
2.5 | Collection of data
All	data	were	prospectively	recorded	as	part	of	routine	clinical	practice.	
A	 structured	 database	 was	 implemented.	 Outcome	 data	 were	 also	
documented	 as	 part	 of	 clinical	 routine.	After	 completion	 of	 2	years	
of	 follow-	up	 in	 the	 course	of	CCP,	 outcome	data	were	 additionally	
collected	over	 the	 course	of	 further	outpatient	 visits	 and	accessing	
MUMC	and	general	practitioner	records.
2.6 | Determination of laboratory tests
Laboratory	 data	were	 determined	 in	 a	 certified	MUMC+	 laboratory	
using	 established	methods	 as	 previously	 described.28	Venous	 blood	
samples	 were	 collected	 in	 commercially	 available	 tubes	 with	 and	
without	 citrate	 0.106	mol/l	 as	 appropriate	 following	 an	 established	
protocol	 to	 ensure	 adequate	 preanalytic	 conditions.	 Samples	 were	
centrifuged	according	 to	 recent	guidelines	 (10	minutes	at	1500	g	or	
5	minutes	 at	2500	g,	 respectively).	D-	dimer	 and	CRP	was	measured	
after	centrifugation.	Plasma	for	factor	VIII	measurements	were	snap-	
frozen	at	−80°C.	D-	dimer	were	determined	using	the	Vidas	assay	until	
F IGURE  1 Flow	of	patients	within	the	clinical	care	pathway	and	study	cohort
Criteria for admission: 
- Proximal lower extremity DVT
- Diagnosed at MUMC between 1st June
2003 and 30th June 2013
- Aged 18 or older
Clinical care pathway started (n = 479)
Clinical care pathway completed (n = 474; 99%)
Moved abroad: n = 5
Extended observation period (n = 457; 94.7%) 
Lost to follow-up: n = 17 
Patients with proximal DVT
Provoked DVT
n = 179; 37.4%
RVT not present
(n = 125; 69.8%)
RVT not present
(n = 127; 59.4%)
RVT not present
(n = 23; 26.7%)
RVT present
(n = 45; 25.1%)
RVT present
(n = 80; 37.4%)
RVT present
(n = 19; 22.1%)
Unprovoked DVT
n = 214; 44.7%
High-risk
n = 86; 17.9%
3 months OAC 6 months OAC 6 months OAC 12 months OAC Indefinite OAC 
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May	2008	(bioMérieux	Clinical	Diagnostics,	Marcy-	l’Etoile,	France)	and	
the	Innovance	assay	from	June	2008	(Siemens	Healthcare,	Marburg,	
Germany).	Factor	VIII	was	determined	using	a	one-	stage	coagulomet-
ric	 assay	 (Actin	 FS;	 Siemens	 Healthcare,	 Marburg,	 Germany).	 Both	
assays	were	run	on	a	Sysmex	CA7000	(Siemens,	Marburg,	Germany).	
CRP	was	determined	with	a	turbidimetric	test	(Synchron	LX	Systems,	
Beckman	Coulter	Inc.,	Fullerton,	CA,	USA).
2.7 | Outcomes, predictor variables, and co- variables
We	 defined	 the	 time	 to	 recurrent	 VTE	 as	 the	 primary	 outcome.	
Recurrent	VTE	was	defined	as	objectively	confirmed	proximal	or	dis-
tal	DVT,	PE,	or	other	venous	thrombosis	as	determined	by	CU,	spi-
ral	 computed	 tomography,	 or	 ventilation-	perfusion	 lung	 scanning.	
Recurrent	DVT	was	defined	as:	(i)	a	new	non-	compressible	vein	in	the	
contralateral	leg,	(ii)	a	new	non-	compressible	vein	of	the	same	leg	as	
the	first	event	(previously	unaffected),	(iii)	a	clear	proximal	extension	
of	the	known	thrombus,	or	(iv)	a	new	non-	compressible	site	of	a	vein	
that	was	effected	but	previously	re-	canalized.11,26,29
Secondary	outcome	was	time	to	death	from	any	cause.	A	number	of	
variables	previously	identified	or	suspected	as	predictors	for	recurrent	
VTE	were	recorded	as	a	potential	predictor	or	a	co-	variable,	 respec-
tively	 (Table	1).4,5,30–32	Periods	of	 oral	 anticoagulation	 administration	
were	 recorded	 and	 represented	 a	 time-	varying	 co-	variate.	 	D-	dimer,	
CRP,	and	factor	VIII	were	measured	one	month	after	cessation	of	an-
ticoagulation	therapy.	All	other	variables	were	considered	at	the	time	
of	diagnosis.	D-	dimer	was	considered	positive	if	≥	500	ng/mL,	CRP	if	≥	
5.0	mg/L	(according	to	recent	recommendations33)	and	factor	VIII	if	≥	
213%	(corresponding	to	the	80th	percentile	of	the	study	population).	
Due	to	organizational	reasons,	bleeding	events	were	not	recorded.
2.8 | Statistical analysis
Incidence	rates	of	 recurrent	VTE	per	100	patient-	years	and	mortal-
ity	 rates	were	 reported	 for	 all	 subgroups.	Cumulative	 incidences	of	
recurrent	VTE	 in	 patients	with	 and	without	 risk	 factors	were	 com-
pared	using	Kaplan–Meier	curves	and	the	 log-	rank	test.	A	Cox	pro-
portional	hazards	model	was	used	to	calculate	associations	between	
predictor	 variables	 and	 recurrent	VTE.	 Estimates	were	 adjusted	 for	
factors	that	were	previously	identified	as	relevant	predictors4,5,30–32: 
age,	sex,	surgery,	pregnancy,	contraceptive	use	at	the	time	of	throm-
bosis,	traveling,	inflammation,	previous	VTE,	D-	dimer,	and	periods	of	
anticoagulation	as	time-	varying	covariate.	Observations	with	missing	
values	were	 excluded	 from	 analysis;	 a	 sensitivity	 analysis	was	 con-
ducted	after	multiple	imputation.	All	analyses	were	conducted	using	
Stata	statistical	software	(StataCorp,	College	Station,	TX,	USA).
3  | RESULTS
3.1 | Patient characteristics
Four-	hundred	and	seventy-	nine	patients	diagnosed	with	proximal	
lower	extremity	DVT	were	treated	within	the	CCP;	the	flow	of	the	
patients	 is	 shown	 in	 Figure	1,	 detailed	 patient	 characteristics	 are	
reported	in	Table	1.	During	the	two-	year	CCP	following	diagnosis,	
five	patients	moved	abroad	(1.0%).	After	finishing	CCP,	17	patients	
were	lost	to	extended	follow-	up	(3.6%).	Finally,	457	patients	were	
followed	 for	 a	median	of	 4.6	years	 equivalent	 to	 2231.2	 patient-	
years	(Table	1).	The	median	age	was	58.0	years	(inter-	quartile	range	
[IQR]	46.1,	71.1;	50.5%	of	the	patients	were	female	(n	=	242).	DVT	
was	 unprovoked	 in	 55.3%	 of	 the	 cases	 (n	=	265).	 RVO	 was	 ob-
served	in	30.1%	of	the	patients	(n	=	144).	Duration	of	anticoagula-
tion	therapy	was	three	months	in	15.7%	of	the	patients	(n	=	75),	six	
months	in	48.0%	(n	=	230),	12	months	in	19.8%	(n	=	95)	and	indefi-
nite	 in	 16.5%	 (n	=	79).	 All	 patients	 received	 vitamin	K	 antagonist	
therapy	 (predominantly	 acenocoumarol).	 RVO	was	 present	 in	 45	
patients	with	 provoked	DVT	 (25.1%),	 in	 80	 patients	with	 unpro-
voked	DVT	(37.4%),	and	in	19	patients	with	high	risk	DVT	(22.1%;	
see	Figure	1).
3.2 | VTE recurrence
Thirty	 seven	 recurrent	 VTE	 were	 observed	 within	 the	 first	 two	
years	of	CCP	follow-	up	and	64	VTE	during	the	extended	follow-	up.	
Type	of	event	was	DVT	 in	39	patients	 (60.9%),	PE	 in	20	patients	
(31.3%),	and	other	venous	thromboembolism	in	five	patients	(7.8%;	
cerebral	venous	sinus	thrombosis	[n	=	1;	1.6%]	and	upper	extrem-
ity	DVT	[n	=	4;	6.3%]).	Ipsilateral	DVT	was	observed	in	29	patients	
(45.3%).
The	overall	 incidence	rate	was	4.2	per	100	patient-	years	for	the	
first	two	years	and	2.9	for	the	extended	observation	period	(Table	2).	
The	Kaplan-	Meier	estimate	of	overall	recurrence	is	shown	in	Figure	1.	
In	patients	with	DVT	provoked	by	surgery,	incidence	rate	was	1.1	per	
100	 patient-	years	 (CCP)	 or	 1.3,	 respectively	 (extended	 observation	
period).	For	patients	with	non-	surgical	transient	risk	factors,	the	inci-
dence	rate	was	3.1	or	2.1,	respectively.	In	contrast,	the	incidence	rate	
was	6.1	or	4.0,	respectively,	in	patients	with	unprovoked	VTE.	The	cu-
mulative	incidence	according	to	these	groups	is	illustrated	in	Figure	3.	
Subgroup	analyses	 revealed	higher	 incidence	 rates	 for	 the	 following	
risk	factors:	male	sex,	traveling	history,	inflammatory	disease,	elevated	
D-	dimer,	 high	 factor	VIII	 and	 elevated	 CRP	 (Table	2).	 Kaplan–Meier	
estimates	are	shown	 in	Figure	3.	No	 recurrent	VTE	events	occurred	
during anticoagulation treatment.
3.3 | Mortality
Twenty-	one	patients	died	during	the	observation	period	resulting	in	
a	mortality	rate	of	2.4	per	100	patient-	years	(CCP),	or	1.5	(extended	
follow-	up),	 respectively.	 The	 highest	mortality	 rates	were	 observed	
among	 patients	 with	 active	 cancer	 (14.6	 or	 17.4	 per	 100	 patient-	
years,	 respectively).	 In	 contrast,	 low	mortality	 rates	 (below	2.0	 and	
1.5	per	100	patient-	years	respectively)	were	recorded	in	patients	with	
non-	surgical	transient	risk	factors,	namely,	previous	VTE,	venous	in-
sufficiency,	a	family	history	of	VTE,	residual	thrombosis	or	high	factor	
VIII.	Details	for	all	subgroups	are	presented	in	Table	S1	(Supplemental	
Material).
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3.4 | Risk factors for recurrent VTE
Unadjusted	and	adjusted	hazard	ratios	 (HR)	are	reported	 in	Table	3.	
Compared	to	patients	with	VTE	provoked	by	surgery,	the	adjusted	HR	
was	1.6	for	non-	surgical	transient	risk	factors	(95%	CI:	0.5,	5.5),	and	
4.6	for	unprovoked	VTE	(95%	CI:	1.7,	11.9).	The	association	between	
active	 cancer	 and	 recurrent	VTE	could	not	be	determined	due	 to	a	
very	low	number	of	patients	in	this	subgroup.	A	statistically	significant	
TABLE  1 Patient	characteristics
Characteristics
Clinical care pathway (n = 479) Extended observation period (n = 474)
Frequency (%) Missing values Frequency (%) Missing values
Observation	period 876	patient-	years	
(median	2)
5a 2231	patient-	years	
(median	5)
17b
Age	(median,	IQR) 58.0	(46.1,	71.1) 0 58.0	(46.1,	71.0) 0
Females 242	(50.5) 0 239	(50.4) 0
Duration	of	anticoagulation	(mutually	exclusive	groups)
 3 months 75	(15.7) 0 75	(15.8) 0
	6	months 230	(48.0) 0 228	(48.10) 0
 12 months 95	(19.8) 0 95	(20.1) 0
	Indefinite 79	(16.5) 0 76	(16.0) 0
Provoking	risk	factors	(mutually	exclusive	groups)
	Provoked	by	surgeryc 95	(19.9) 0 95	(20.0) 0
	Non-	surgical	transient	risk	factorc 107	(22.3) 0 106	(22.4) 0
	Unprovoked	VTEc 265	(55.3) 0 261	(55.1) 0
 Active cancerc 12	(2.5) 0 12	(2.5) 0
Other	risk	factors
	Pregnancyd 6	(1.3) 0 6	(1.3) 0
	Contraceptive	use	at	the	time	of	thrombosisd 50	(10.4) 6 50	(10.6) 6
 Traveld 34	(7.1) 0 34	(7.2) 0
	Immobilizationd 40	(8.4) 6 39	(8.2) 6
	Inflammationd 64	(13.4) 7 63	(13.3) 7
	Previous	VTEd 91	(19.0) 0 90	(19.0) 0
	Cardiovascular	diseased 115	(24.0) 5 115	(24.3) 5
	Heart	failured 6	(1.3) 6 6	(1.3) 6
	Known	thrombophiliad 19	(4.0) 7 18	(3.8) 7
	Venous	insufficiencyd 31	(6.5) 8 31	(6.5) 8
	Varicosisd 22	(4.6) 177 22	(4.6) 173
 Residual thrombosisd,e 144	(30.1) 60 141	(29.8) 58
	Smokingd 107	(22.3) 29 106	(22.4) 26
 Family historyd 140	(29.2) 14 138	(29.1) 14
Risk	factors	not	assessed	at	baseline
	Elevated	D-	dimerd,f 112	(23.4) 122 112	(23.6) 119
	Elevated	CRPd,f 109	(22.8) 174 109	(23.0) 171
	Elevated	FVIIId& 65	(13.6) 157 65	(13.7) 153
	Elevated	Villalta	scored,g,h 78	(16.3) 96 78	(16.5) 94
CRP,	C-reactive	protein;	IQR,	inter-quartile	range;	VTE,	venous	thromboembolism.
aMoved	abroad.
bLost	to	follow-	up.
cMutually	exclusive	groups.
dPatients	can	be	subject	to	more	than	one	risk	factor.
eOne	week	before	intended	stop	of	OAC.
fOne	month	after	stopping	OAC.
gAt six months.
h≥5	points	&	≥213%;	corresponding	to	the	80th	percentile	of	the	study	population.
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association	with	recurrence	of	VTE	was	observed	for	a	number	of	ad-
ditional	predictors	 (Table	3):	male	sex	 (HR	2.8;	95%CI:	1.5,	5.1),	use	
of	contraceptives	at	the	time	of	thrombosis	(HR	0.1;	95%CI	0.0,	0.9),	
elevated	D-	dimer	(HR	3.3;	95%	CI	1.8,	6.1);	and	high	factor	VIII	(HR	
2.2;	95%CI:	1.2,	4.0).
4  | DISCUSSION
In	our	study	of	a	cohort	of	patients	with	proximal	DVT	who	were	man-
aged	with	a	CCP	that	incorporated	the	presence	of	RVO,	we	found	that	
predictors	of	recurrent	VTE	were	unprovoked	VTE,	elevated	D-	dimer	
1	month	 after	 anticoagulant	 treatment	 was	 stopped,	 male	 sex,	 and	
high	factor	VIII.	We	also	documented	that	99%	of	patients	diagnosed	
with	proximal	DVT	and	treated	within	the	CCP	completed	the	2	year	
treatment	protocol,	 the	overall	 rate	of	 recurrence	was	 relatively	 low,	
and	recurrence	rates	were	lowest	in	women	with	VTE	provoked	by	oral	
contraceptives.
Minimal	data	is	available	on	clinical	outcomes	of	patients	treated	
within	a	particular	CCP	or	treatment	program,	and	research	to	date	
has	instead	focused	on	the	short-	term	management.	Tillman	and	col-
leagues	evaluated	an	outpatient	DVT	treatment	program	in	391	pa-
tients19	resulting	in	a	VTE	incidence	rate	of	6.0	per	100	patient-	years.	
An	elevated	risk	of	mortality	was	stated	in	a	different	cohort	of	131	
patients,	but	no	incidence	rates	were	reported.34	Equivalent	numbers	
of	recurrent	VTE	compared	to	usual	care	were	recorded	in	another	
CCP	in	the	community	setting,	but	only	short-	term	effects	were	ob-
served.17 There have been several other investigations studying small 
cohorts,	 but	 few	 or	 no	 clinical	 outcomes	were	 reported.17,35–38	 In	
contrast,	we	studied	the	long-	term	clinical	outcomes	in	large	cohort	
of	patients	treated	within	a	defined	CCP	considering	risk	assessment	
and	 long-	term	 treatment	 strategies.32	 In	 accordance	with	 previous	
investigations,	patients	with	unprovoked	VTE	were	found	to	carry	a	
high	risk	of	recurrence.32	Both	observational	data39–41 and interven-
tional	 studies	have	also	confirmed	 the	predictive	value	of	elevated	
D-	dimer	1	month	after	cessation	of	treatment	for	VTE	recurrence.42 
Men	had	a	higher	risk	of	recurrence	than	women,	 in	our	setting	as	
well as in others.43,44	In	contrast	to	earlier	cohorts,	risk	of	recurrence	
was	very	low	in	patients	taking	estrogen	containing	contraceptives	at	
the	time	of	thrombosis.45	This	difference	is	most	probably	reflected	
by	 the	 increased	 awareness	 of	 the	 associated	 risk	 and	 the	 subse-
quent	strict	avoidance	of	estrogen-	containing	drugs	in	patients	that	
have	suffered	from	VTE.	 In	 line	with	previous	data,	high	factor	VIII	
was associated with recurrent thromboembolism.46,47	 In	 addition,	
inflammatory	 conditions,	 as	well	 as	 elevated	 CRP	were	 associated	
with	VTE	recurrence,	at	 least	 in	the	univariate	analysis.48	RVO	was	
not	associated	with	recurrent	VTE,11	perhaps	because	the	duration	
of	anticoagulation	was	tailored	according	to	the	presence	of	RVO	in	
this	CCP.
We	are,	however,	faced	with	some	limitations.	The	number	of	
patients	and	recurrent	events	were	 limited,	resulting	 in	 imprecise	
estimations	 for	 some	 of	 the	more	 infrequent	 predictor	 variables	
or	those	with	a	smaller	effect.	This	effect	was	intensified	by	a	rel-
evant	 number	 of	missing	values	with	 regard	 to	 the	variables	 not	
assessed	at	baseline.	However,	we	did	not	find	apparent	discrepan-
cies	in	sensitivity	analyses	(eg,	after	multiple	imputation).	Another	
limitation	 is	 that	 only	 very	 few	 patients	with	 active	 cancer	were	
included	in	our	cohort.	Thus,	the	results	of	our	investigation	can-
not	be	extended	to	this	specific	population.49 Also concerning the 
efficacy	of	the	management	strategy	some	limitations	have	to	be	
considered.	We	were	 not	 able	 to	 record	 bleeding	 events	 due	 to	
organizational	 reasons.	Therefore,	 our	 conclusions	 are	 limited	 to	
the	 efficacy	 of	 the	 CCP.	Moreover,	we	 did	 not	 implement	 a	 for-
mal	assessment	of	the	compliance	with	the	CCP.	The	risk	of	rele-
vant	protocol-	deviations	is	however	estimated	to	be	low	because	
the	 duration	 of	 anticoagulation	 fits	well	with	 the	 risk	 categories	
(85%	 of	 patients	 with	 provoked	 DVT	 were	 treated	 three	 to	 six	
months,	94%	of	patients	with	unprovoked	DVT	were	treated	six	to	
12	month,	and	92%	of	high-	risk	patients	were	treated	indefinitely).	
In	this	study,	as	in	many	others,7,8,10,50–55	we	did	not	formally	asses	
the	inter-	observer	agreement	with	regard	to	RVO.	We	cannot	fully	
exclude	that	this	might	have	introduced	a	certain	variability	of	re-
sults,	 obscuring	a	possible	effect	on	clinical	outcomes.	However,	
this	 reflects	 clinical	 practice	 of	 a	 clinical	 care	 pathway.	 Another	
limitation	is	that	we	did	not	record	if	the	recurrent	event	was	pro-
voked	or	unprovoked.
Our	 investigation	 has	 several	 strengths.	 Firstly,	 it	 is	 one	 of	 the	
first	studies	 investigating	clinical	outcomes	of	DVT	patients	treated	
within	a	CCP	and	the	first	study	investigating	a	management	incorpo-
rating	RVO	in	clinical	practice.	Secondly,	we	have	conducted	a	long-	
term	follow	up,	 facilitating	 long-	term	predictions	and	counseling	of	
patients.
CCPs	aim	 to	 translate	evidence-	based	medicine	 into	clinical	prac-
tice,	 improve	collaboration	among	multiple	specialized	caregivers,	and	
standardize	health-	care	procedures.	In	addition	the	structured	manage-
ment	and	follow	up	of	a	CCP	allows	for	prospective	collection	of	data	on	
F IGURE  2 Cumulative	incidence	of	VTE	recurrence	in	patients	
managed	in	a	clinical	care	pathway	incorporating	the	presence	of	
residual	vein	obstruction.	The	overall	incidence	rate	was	2.9	per	100	
patient-	years
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clinical	outcomes	and	identification	of	predictive	factors	for	outcomes	of	
interest.	Our	data	support	previous	studies	suggesting	an	implementa-
tion	of	a	CCP	for	treatment	of	DVT	in	clinical	practice	and	suggest	that	
management	incorporating	the	presence	of	RVO	might	be	beneficial.
In	 conclusion,	 in	 this	 study	we	 have	 demonstrated	 that	 long-	term	
VTE	 recurrence	 rates	 and	mortality	 are	 low	 in	DVT	patients	managed	
within	a	CCP	incorporating	the	presence	of	RVO.	Recurrence	rates	were	
lowest	in	women	with	VTE	provoked	by	oral	contraceptives.	Major	risk	
TABLE  2  Incidence	rate	of	recurrent	venous	thromboembolic	events	by	risk	factors
Risk factors
Clinical care pathway Extended observation period
Events frequency
Observation time 
patient- years
Incidence rate (95% CI) 
per 100 patient- years Events frequency
Observation time 
patient- years
Incidence rate (95% CI) 
per 100 patient- years
Total 37 876 4.2	(3.1,	5.8) 64 2231 2.9	(2.2,	3.7)
Provoking	risk	factors	(mutually	exclusive	groups)
Provoked	by	
surgery
2 186 1.1	(0.3,	4.3) 6 475 1.3	(0.6,	2.8)
Non-	surgical	
transient	risk	
factor
6 192 3.1	(1.4,	7.0) 11 519 2.1	(1.2,	3.8)
Unprovoked	VTE 29 478 6.1	(4.2,	8.7) 47 1186 4.0	(3.0,	5.3)
Active cancer 0 21 N/A 0 52 N/A
Other	risk	factors
Male	sex 26 429 6.1	(4.1,	8.9) 41 1042 3.9	(2.9,	5.3)
Female sex 11 447 2.5	(1.4,	4.4) 23 1190 1.9	(1.3,	2.9)
Pregnancy 0 11 N/A 1 30 3.3	(0.5,	23.7)
Contraceptive	use	
at	the	time	of	
thrombosis
0 94 N/A 1 270 0.4	(0.0,	2.6)
Travel 4 60 6.6	(2.5,	17.7) 8 175 4.6	(2.2,	3.7)
Immobilization 2 69 2.9	(0.7,	11.5) 2 168 1.2	(0.3,	4.8)
Inflammation 8 117 6.8	(0.3,	13.7) 15 317 4.7	(2.9,	7.9)
Previous	VTE 2 175 1.1	(0.3,	4.6) 10 492 2.0	(1.1,	3.8)
Cardiovascular	
disease
10 209 4.8	(2.6,	8.9) 17 467 3.6	(2.3,	5.9)
Heart	failure 0 12 N/A 1 33 3.0	(0.4,	21.6)
Known	
thrombophilia
0 36 N/A 1 91 1.1	(0.2,	7.8)
Venous	
insufficiency
0 59 N/A 0 106 N/A
Varicose	veins 1 43 2.3	(0.3,	16.4) 3 139 2.2	(0.7,	6.7)
Smoking 7 200 3.5	(1.7,	7.4) 13 524 2.5	(1.4,	4.3)
Family history 10 260 3.9	(2.1,	7.2) 17 659 2.6	(1.6,	4.1)
Risk	factors	not	assessed	at	baseline
Residual vein 
obstructiona
12 270 4.4	(2.5,	7.8) 22 689 3.2	(2.1,	4.8)
Elevated	Villalta	
scoreb,d
6 148 4.0	(1.8,	9.0) 14 362 3.9	(2.3,	6.5)
Elevated	D-	dimerc 17 197 8.6	(5.4,	13.9) 26 514 5.1	(3.4,	7.4)
High	factor	VIIIc 9 120 7.5	(3.9,	14.5) 17 329 5.2	(3.2,	8.3)
Elevated	CRPc 11 201 5.5	(3.0,	9.9) 22 537 4.1	(2.7,	6.2)
aAssessed	one	week	before	intended	cessation	of	anticoagulation	treatment.
bAssessed at six months.
cAssessed	one	month	after	stopping	OAC.
d≥5	points.
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factors	 for	VTE	 recurrence	were	 unprovoked	VTE,	male	 sex,	 elevated	 
D-	dimer,	as	well	as	factor	VIII	one	month	after	cessation	of	treatment,	
and	inflammation.
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F IGURE  3 Cumulative	incidence	of	VTE	recurrence	according	to	the	presence	of	risk	factors.	(A)	Unprovoked	VTE,	non-	surgical	transient	
risk	factor,	provoked	by	surgery	(mutually	exclusive	groups);	Incidence	rates	were	1.3	per	100	patient-	years	if	provoked	by	surgery,	2.1	if	a	
non-	surgical	transient	risk	factor	was	present	and	4.0	if	unprovoked;	(B)	Sex;	(C)	Elevated	D-	dimer	one	month	after	cessation	of	anticoagulant	
treatment;	(D)	Use	of	contraceptives	at	the	time	of	thrombosis;	(E)	High	factor	VIII;	and	(F)	Presence	of	inflammation
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